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Abstract. 
 
The syndecan family of four transmembrane 
heparan sulfate proteoglycans binds a variety of soluble 
and insoluble extracellular effectors. Syndecan extra-
cellular domains (ectodomains) can be shed intact by 
proteolytic cleavage of their core proteins, yielding sol-
uble proteoglycans that retain the binding properties of 
their cell surface precursors. Shedding is accelerated by 
PMA activation of protein kinase C, and by ligand acti-
vation of the thrombin (G-protein–coupled) and EGF 
(protein tyrosine kinase) receptors (Subramanian, S.V., 
M.L. Fitzgerald, and M. Bernﬁeld. 1997. 
 
J
 
.
 
 Biol
 
.
 
 Chem
 
. 
272:14713–14720). Syndecan-1 and -4 ectodomains are 
found in acute dermal wound ﬂuids, where they regu-
late growth factor activity (Kato, M., H. Wang, V. 
Kainulainen, M.L. Fitzgerald, S. Ledbetter, D.M. Or-
nitz, and M. Bernﬁeld. 1998. 
 
Nat. Med
 
. 4:691–697) and 
proteolytic balance (Kainulainen, V., H. Wang, C. 
Schick, and M. Bernﬁeld. 1998. 
 
J. Biol
 
.
 
 Chem
 
. 273:
11563–11569). However, little is known about how
syndecan ectodomain shedding is regulated.
To elucidate the mechanisms that regulate syndecan 
shedding, we analyzed several features of the process 
that sheds the syndecan-1 and -4 ectodomains. We ﬁnd 
that shedding accelerated by various physiologic agents 
involves activation of distinct intracellular signaling 
pathways; and the proteolytic activity responsible for 
cleavage of syndecan core proteins, which is associated 
with the cell surface, can act on unstimulated adjacent 
cells, and is speciﬁcally inhibited by TIMP-3, a matrix-
associated metalloproteinase inhibitor. In addition, we 
ﬁnd that the syndecan-1 core protein is cleaved on the 
cell surface at a juxtamembrane site; and the pro-
teolytic activity responsible for accelerated shedding 
differs from that involved in constitutive shedding of 
the syndecan ectodomains. These results demonstrate 
the existence of highly regulated mechanisms that can 
rapidly convert syndecans from cell surface receptors 
or coreceptors to soluble heparan sulfate proteoglycan 
effectors. Because the shed ectodomains are found and 
function in vivo, regulation of syndecan ectodomain 
shedding by physiological mediators indicates that 
shedding is a response to speciﬁc developmental and 
pathophysiological cues.
Key words: cellular stress • heparan sulfate •
mitogen-activated protein kinase • protein tyrosine
kinase • proteoglycan
 
Introduction
 
The extracellular domains (ectodomains) of 
 
z
 
1% of mem-
brane-anchored proteins can be released from the cell
surface by endogenous proteolytic cleavage in a process
known as ectodomain shedding (Hooper et al., 1997;
Kiessling and Gordon, 1998; Werb and Yan, 1998; Hooper
and Turner, 1999). These proteins are structurally and
functionally diverse and include the following: cytokines,
growth factors and their receptors, ectoenzymes, cell ad-
hesion molecules, and other transmembrane proteins,
such as transforming growth factor-
 
a
 
, tumor necrosis fac-
tor (TNF)
 
1
 
-
 
a
 
, TNF receptors, interleukin 6 receptor, an-
giotensin-converting enzyme, L-selectin, the Fas ligand,
and the 
 
b
 
-amyloid precursor protein. Shedding liberates
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Abbreviations used in this paper:
 
 4
 
a
 
PDD, 4
 
a
 
-phorbol-12, 13-didecanoate;
AU, absorbance units; ECL, enhanced chemiluminescence; ERK, extra-
cellular signal-related kinase; HSPG, heparan sulfate proteoglycan; JM,
juxtamembrane; JNK, c-Jun NH
 
2
 
-terminal kinase; MAP kinase, mitogen-
activated kinase; MMP, matrix metalloproteinase; MP, metalloproteinase;
PKC, protein kinase C; PTK, protein tyrosine kinase; SAPK, stress-acti-
vated protein kinase; TIMP, tissue inhibitor of metalloproteinase; TNF,
tumor necrosis factor; TRAP, thrombin receptor agonist peptide. 
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ectodomains as soluble molecules and can reduce their
concentration at the cell surface. Phorbol esters, such as
PMA, are the best characterized shedding agonists, but
ectodomain shedding can also be induced by other agents,
including calcium ionophores, chemotactic peptides, cy-
tokines, and growth factors (Hooper et al., 1997; Subra-
manian et al., 1997; Desdouits-Magnen et al., 1998; Jones
et al., 1999). Shed ectodomains are detected in vivo in
various body fluids, and their levels are often increased by
tissue injury and in certain disease states (Ehlers and
Riordan, 1991; Gearing and Newman, 1993; Abraham
and Klagsbrun, 1996; Hooper et al., 1997; Hooper and
Turner, 1999).
Ectodomain shedding appears to contribute to diverse
pathophysiological events such as host defense, wound
healing, arthritis, and Alzheimer’s disease, but how shed-
ding is regulated remains largely unknown (Kiessling and
Gordon, 1998; Hooper and Turner, 1999; Merlos-Suarez
and Arribas, 1999). The cleavage process, variously as-
cribed to sheddases, secretases, or convertases, has several
shared features, leading to the proposal of a common
shedding system (Arribas et al., 1996; Mullberg et al.,
1997). Cleavage is enhanced by phorbol ester activation of
protein kinase C (PKC), is generally close to the extracel-
lular face of the plasma membrane, and is sensitive to
peptide hydroxamate metalloproteinase (MP) inhibitors
(Hooper et al., 1997; Hooper and Turner, 1999).
The intact ectodomains of each mammalian syndecan
and the single 
 
Drosophila
 
 syndecan are constitutively
shed from cultured cells (Kim et al., 1994; Spring et al.,
1994) as part of normal cell surface HSPG turnover
(Yanagishita and Hascall, 1992; Yanagishita, 1998). The
syndecans are a family of transmembrane heparan sulfate
proteoglycans (HSPGs) which, together with the lipid-
linked glypicans, are the major source of HS at cell sur-
faces (Bernfield et al., 1992, 1999). All adhesive cells ex-
press at least one syndecan, and most express multiple
syndecans (Kim et al., 1994). The core proteins of each of
these four distinct gene products place the HS chains dis-
tal from the plasma membrane. Each syndecan contains
at its COOH terminus a short and highly homologous cy-
toplasmic domain with serine and tyrosine residues at
conserved positions.
By way of their HS chains, syndecans bind a wide vari-
ety of soluble and insoluble ligands, such as follows: ex-
tracellular matrix components, cell adhesion molecules,
growth factors, cytokines, proteinases and proteinase in-
hibitors, lipid metabolism proteins, and microbial patho-
gens (Bernfield et al., 1992; Carey, 1997; Bernfield et al.,
1999). Syndecans facilitate the formation of signaling com-
plexes by acting as coreceptors, concentrating and present-
ing ligands to the cell surface receptors, or internalizing
them via endocytosis, thus, modulating ligand activities
(Bernfield et al., 1999).
Because the HS chains of the cell surface and shed syn-
decans can bind the same ligands, syndecan ectodomain
shedding is a mechanism for producing soluble HSPG ef-
fectors that can compete for the same ligands as their cell
surface counterparts. Shedding of syndecan-1 and -4 can
be accelerated via receptor activation (e.g., thrombin and
EGF family members) and by direct action of proteases
(e.g., plasmin and thrombin; Subramanian et al., 1997).
These ectodomains are in fluids accumulating following in-
jury and inflammation (Subramanian et al., 1997; Kato et
al., 1998), but not in normal human plasma (Subramanian et
al., 1997). The soluble syndecan-1 ectodomain potently in-
hibits heparin-mediated FGF-2 mitogenicity (Kato et al.,
1998), which is consistent with studies indicating that the
shed ectodomains can inhibit cell proliferation (Mali et al.,
1994; Forsten et al., 1997; Dhodapkar and Sanderson,
1999), and binds neutrophil-derived elastase and cathepsin
G, reducing the action of their physiological inhibitors
(Kainulainen et al., 1998). These activities are consistent
with a role for the soluble syndecan ectodomains in the re-
sponse to tissue injury.
While syndecan ectodomain shedding is known to be ac-
tivated by physiological stimulants (Subramanian et al.,
1997) and the ectodomains are being ascribed pathophysi-
ological roles, little is known about how their release from
the cell surface is regulated. Therefore, we analyzed sev-
eral features of the process that sheds the syndecan-1 and
-4 ectodomains. We find that syndecan shedding is regu-
lated at multiple levels, based on the following findings:
(1) that in addition to proteases and receptor ligands,
agents that mediate cellular responses to stress accelerate
shedding; (2) shedding accelerated by various physiologi-
cal agents involves activation of distinct intracellular sig-
naling pathways; (3) the proteolytic activity responsible
for cleavage of syndecan core proteins is associated with
the cell surface, and is a TIMP-3–sensitive MP that can act
on unstimulated adjacent cells; (4) the syndecan-1 core
protein is cleaved on the cell surface at a juxtamembrane
site; and (5) the proteolytic activity responsible for accel-
erated shedding differs from that involved in constitutive
shedding. These results demonstrate the existence of
highly regulated mechanisms that convert syndecans from
cell surface receptors or coreceptors to soluble HSPG ef-
fectors. Regulation of shedding by physiological mediators
suggests that syndecan ectodomains are shed in response
to specific developmental and pathophysiological cues.
Now soluble, the shed syndecan ectodomains likely have
roles in morphogenesis, tissue repair, and host defense. Pre-
liminary reports of this study have been presented in ab-
stract form (Fitzgerald, M.L., J.-S. Chun, and M. Bernfield,
American Society of Cell Biology. 1994. 1813 (Abstr.);
Fitzgerald, M.L., and M. Bernfield, American Society of Cell
Biology. 1997. 2286 (Abstr.); Fitzgerald, M.L., Z. Wang, and
M. Bernfield, American Society of Cell Biology. 1998. 326
(Abstr.)).
 
Materials and Methods
 
Materials and Chemicals
 
Ceramide (
 
D
 
-erythro-Sphingosine, 
 
N
 
-Acetyl), EDTA, 1,10 phenanthro-
line, phosphoramidon, actinonin, benzamidine, E-64, leupeptin, pepstatin
A, colchicine, cytochalasin D, wortmannin, sphingomyelinase, sorbitol,
and MTT (tetrazolium salt) were purchased from Sigma Chemical Co.;
LY 294002 from BioMol Research Labs; paraformaldehyde (16%) from
Electron Microscopy Sciences; recombinant human (rHu) EGF from In-
tergen; PMA, 4
 
a
 
-phorbol-12, 13-didecanoate (4
 
a
 
PDD), thrombin recep-
tor agonist peptide (TRAP), PMSF, staurosporine, bisindolylmaleimide I,
genistein, PD 98059, and SB 202190 were purchased from Calbiochem-
Novabiochem. Tyrphostin A25 and methyl 2,5-dihydroxycinnamate were 
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purchased from Toronto Research Chemicals, and peptide hydroxamates
BB-2116, BB-1101, and control compound BB-3861 were gifts from Dr.
Alan Drummond (British Biotech Pharmaceuticals Ltd, Oxford, UK). Re-
combinant human (rHu) TIMP-1, -2, and -3 were expressed and purified
from NSO mouse myeloma cells (Apte et al., 1995; Murphy and Willen-
brock, 1995). All three inhibitors were active site–titrated against a stan-
dard preparation of stromelysin, and calibrated using an inhibitor stan-
dard to confirm that they were 
 
.
 
95% functional protein as previously
described (Murphy and Willenbrock, 1995).
 
Immunochemicals
 
Antibodies specific to syndecan ectodomains included the rat mAb 281-2
against the mouse syndecan-1 ectodomain (Jalkanen et al., 1985), rabbit
polyclonal antisera MSE-4 against the recombinant mouse syndecan-4
ectodomain (Kim et al., 1994; Subramanian et al., 1997), and the mouse
mAb DL-101 against the recombinant human syndecan-1 ectodomain
(Kainulainen et al., 1998). HRP-conjugated donkey anti–rat IgG, HRP-
goat anti–rabbit IgG, HRP-goat anti–mouse IgG, and FITC-conjugated
streptavidin were purchased from Jackson ImmunoResearch Laborato-
ries, Inc., or Organon/Cappel.
 
Production of Full-length Syndecan-1 Fusion 
Constructs with Wild-type or Mutated Juxtamembrane 
(JM) Domains
 
Expression vectors for the synthesis of full-length syndecan-1 with both
wild-type and mutated juxtamembrane domains were used for transient
transfection shedding assays. A full-length expression vector in which the
HindIII fragment containing the full-length murine syndecan-1 from
LK444 (Kato et al., 1995) was inserted into the HindIII site of pcDNA3
(Invitrogen Corp.). The correct orientation was confirmed by restriction
mapping, and this expression vector was designated syn1-WTJM.
To obtain a putative uncleavable syndecan-1 mutant, the JM domain of
syndecan-1 spanning from Gln
 
238
 
 to Gln
 
252
 
 was replaced with the amino
acid sequence of the corresponding JM domain of human CD4 (CD4-JM)
(Hodge et al., 1991) using PCR with pfu DNA polymerase. The following
oligonucleotides were used: the human CD4 JM region containing nucle-
otides 1,225–1,269 of the human CD4 cDNA was amplified using oligo A,
5
 
9
 
-CAGCCCCCGGTGGACGTCAAGGTCTGCCC-3
 
9
 
, and oligo B,
5
 
9
 
GACACCTCCCAGCACGGCCATTGGCGCAC-3
 
9
 
. The 5
 
9
 
 region of
syndecan-1 containing nucleotides 214–953 of the murine syndecan-1
cDNA (Saunders et al., 1989) was amplified using oligos C, 5
 
9
 
-CAC-
AAGCTTCCCGCCGCCGGTCTG-3
 
9
 
, and D, 5
 
9
 
-GGGCAGAACCT-
TGACGTCCACCGGGGGCTG-3
 
9
 
. The 3
 
9
 
 region of syndecan-1 con-
taining nucleotides 995–1,379 was amplified using oligos E, 5
 
9
 
-
CTTCTAGGCGGATCCCAAAGGAGG-3
 
9
 
, and F, 5
 
9
 
-GTGCAGC-
CAATGGCCGTGCTGGGAGGTGTC-3
 
9
 
. The three fragments were
gel-purified and used to construct the putative uncleavable construct using
PCR with pfu DNA polymerase. The resulting PCR product was sub-
cloned into a pCR3 vector (Invitrogen Corp.) and sequenced. The synde-
can-1/CD4-JM fragment was subcloned into the HindIII and BamHI sites
of pcDNA3 and designated as syn1-CD4JM.
 
Cell Lines and Culture Conditions
 
Nonadherent suspension cell lines (plasma cells P3X63 Ag8.653 [murine]
and ARK [human]; Ridley et al., 1993) stimulated with PMA were used
for immunofluorescence and cell mixing experiments. Adherent cells
(NMuMG epithelial and SVEC4-10 endothelial) were used to assay shed-
ding agonists. PMA was used in serum-free media and incubations were
performed for 15–30 min. Other agonists were assayed in media contain-
ing 1% FCS and routinely incubated for 2 or 14 h when constitutive shed-
ding was measured. COS-7 African green monkey kidney cells were used
for cleavage site analysis.
Nonadherent cells were cultured in RPMI 1640 medium containing glu-
cose at 4.5 g/l (Mediatech), supplemented with 10% heat-inactivated FCS.
Adherent cells were cultured in DME containing glucose at 4.5 g/l (Me-
diatech), and supplemented with 10% (SVEC4-10) or 7.5% (NMuMG)
FCS (Intergen). COS-7 cells were cultured in DME containing glucose at
1 g/l, and supplemented with 10% FCS. Cells were cultured in a humidi-
fied incubator containing 5% CO
 
2
 
.
 
Cell Surface Labeling and Fluorescence Analysis
of Syndecan-1
 
P3X63 cells were incubated with 20 
 
m
 
g/ml biotinylated mAb 281-2 for 30
min on ice (conditions that prevent shedding) with gentle agitation,
washed twice by centrifugation at 200 
 
g
 
 at 4
 
8
 
C to remove unbound mAb,
and incubated (10
 
6
 
 cells/tube) for 30 min at 37
 
8
 
C with or without 0.5 
 
m
 
M
PMA. All washes and incubations were done in serum-free RPMI 1640
media. After treatment, cells were fixed in 4% paraformaldehyde in PBS
for 15 min at 4
 
8
 
C, washed in PBS, and incubated with FITC-conjugated
streptavidin for 30 min at room temperature. Cells labeled with FITC-
streptavidin only were included as controls for nonspecific staining. Cells
were washed in PBS, mounted in ProLong Antifade (Molecular Probes,
Inc.), and viewed on a Zeiss Axiophot microscope equipped with epifluo-
rescence and a 100
 
3
 
 PlanApo oil immersion objective. Samples were pho-
tographed with Kodak TMAX 400 film exposed at ASA 800.
 
Shedding Assays
 
Adherent cells were cultured to confluency in 96-well tissue culture plates
for PMA treatment and constitutive shedding assays, or in 6-well plates
for treatment with other agonists. Nonadherent cells were routinely trans-
ferred to 1.5-ml microcentrifuge tubes (
 
z
 
10
 
6
 
 cells/tube) for PMA treat-
ment, as described below. Shedding assays were performed essentially as
previously described (Subramanian et al., 1997). In brief, at the time of
the assay, culture media were replaced with fresh media containing the in-
dicated test agents in the absence of serum (PMA treatment) or in the
presence of 1% FCS (2- and 14-h assays). Cells were incubated at 37
 
8
 
C for
15–30 min (PMA treatment), 2 h (other agonists), or 14 h (constitutive
shedding). After incubations, cells were examined by phase microscopy
for survival and morphology, and the conditioned media were harvested
for dot blot analysis. The 96-well plate assays were performed in triplicate
using 100 
 
m
 
l of media per well; 90 
 
m
 
l of media was used for dot blot analy-
sis. The 6-well plate assays contained 600 
 
m
 
l of media per well, which was
divided into three equal portions for the dot blot analysis. To evaluate
changes in cell number after EGF and TRAP treatment, in some assays,
cells were trypsinized and counted with a hemocytometer after incuba-
tion. For assays using hyperosmolarity, ceramide, and sphingomyelinase,
cell viability was measured using the tetrazolium salt (MTT) conversion
assay (Hansen et al., 1989). Within each experiment, there was no signifi-
cant difference in cell number or viability after the different treatments.
All assays were performed at least twice.
To determine whether the proteolytic activity responsible for shedding
is soluble or membrane-associated, P3X63 cells were coincubated for 15
min at 37
 
8
 
C with human ARK cells that had been pretreated with or with-
out 0.5 
 
m
 
M PMA for 15 min at 37
 
8
 
C and washed twice with serum-free
media. Cells were mixed together in 1.5-ml microcentrifuge tubes or sepa-
rated from each other by a Transwell insert (6.5 mm; Costar Corp.) con-
taining a polycarbonate filter with 0.4-
 
m
 
m pores. In both the cell mixing
and Transwell assays, a constant number of P3X63 cells (5 
 
3
 
 10
 
6
 
) and a
varying number of ARK cells were used. Conditioned media were divided
into three equal portions and analyzed by dot blot analysis using mAb
281-2 to detect syndecan-1 shed from the untreated P3X63 cells. The same
assay was also done using PMA-treated P3X63 cells and untreated ARK
cells, but the conditioned media were analyzed by dot blot using mAb
DL-101 to detect human syndecan-1.
To determine whether the putative uncleavable mutant ectodomain is
shed in response to PMA treatment, wild-type plasmids (syn1-WTJM)
and plasmids containing the syn1-CD4JM mutant were transiently trans-
fected into COS-7 cells using Lipofectamine (Life Technologies, Inc.).
Cells were cultured in 100-mm tissue culture plates (Falcon) for transient
transfections. Cells were trypsinized 24 h after transfection and replated in
6-well plates for shedding assays at 36–48 h after transfection. Cell surface
expression of syndecan-1 was confirmed by immunocytochemistry using
mAb 281-2. The two constructs were shown to be expressed at equivalent
levels by dot blot analysis of supernatants collected after trypsinization of
cells to remove cell surface syndecan-1, as previously described (Subrama-
nian et al., 1997).
 
Dot Immunoassay
 
Specificity and quantitation of the dot immunoassay for shed syndecan-1
and -4 ectodomains has been described previously (Subramanian et al.,
1997). In brief, the conditioned media were diluted in buffer A (0.15 M
NaCl buffered to pH 4.5 with 50 mM sodium acetate, and with 0.1%
Triton X-100), and applied to cationic polyvinylidine difluoride–based 
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membranes (Immobilon-N; Millipore) under mild vacuum in an immu-
nodot apparatus (V&P Scientific). By acidifying the samples in buffer A,
only highly anionic molecules in the conditioned media, such as proteogly-
cans, are retained by the cationic Immobilon-N membrane while most
proteins are cationic at this pH and pass through the membrane. The
membranes were washed twice with buffer A, blocked for 1 h with Blotto
(3% Carnation instant nonfat dry milk, 0.15 M NaCl in 10 mM Tris, pH
7.4), incubated with 1.12 
 
m
 
g/ml of mAb 281-2, 3.6 
 
m
 
g/ml mAb DL-101, or
a 1:1,000 dilution of MSE-4 antiserum, washed with TBS containing 0.3%
Tween 20, and incubated with a 5,000-fold dilution of HRP-conjugated
anti-rat, anti-mouse, or anti-rabbit IgG, respectively. All antibodies were
diluted in Blotto with 0.3% Tween 20.
Detection was by the ECL system (Amersham) as described by the
manufacturer. Results were quantified by scanning the exposed X-ray film
with a Hewlett Packard Scan Jet IVC running the DeskScan II software
package, and using area measurements from NIH Image (V. 1.57 or 1.60)
software. Experimental values were within the linear range of the assay.
Results are expressed as the amount of syndecan shed in relative absor-
bance units (AU). AU varied between experiments, in part, because of
differences in exposure times and because of differences in treatment pa-
rameters. Thus, AUs cannot be compared between experiments. Each
point represents the mean 
 
6 
 
SD of triplicate determinations. Statistical
significance was calculated using the 
 
t
 
 test with the InStat biostatistic pro-
gram (
 
P
 
 , 
 
0.01).
 
Results
 
This study extends our previous work showing that shed-
ding of syndecan ectodomains can be accelerated by phys-
iological agonists (Subramanian et al., 1997). We have now
studied regulation of this shedding using a pharmacologi-
cal approach under defined conditions (PMA in serum-
free medium for 15–30 min and other agonists in 1% FCS
for 2 h) and have identified several aspects, including the
proteolytic activity, involved in its regulation.
 
Inhibition of Tyrosine Kinase Activity Prevents 
Shedding Accelerated by PMA, Receptor Activation, 
and Cellular Stress
 
We previously showed that the tyrosine kinase inhibitor,
genistein, blocked shedding of syndecan-1 and -4 ecto-
domains accelerated by receptor activation, suggesting
that tyrosine phosphorylation is involved in accelerated
shedding (Subramanian et al., 1997). Using NMuMG cells,
we have now asked whether shedding accelerated by
PMA, TRAP, and cellular stress (e.g., ceramide and hy-
perosmolarity) involves tyrosine kinase activity.
Phorbol esters, PKC activators known to enhance ec-
todomain shedding of a diverse group of cell surface pro-
teins (Hooper et al., 1997), rapidly (5 min) accelerate
shedding of syndecan-1 and -4 ectodomains from a variety
of cultured cells (Fitzgerald, M.L., J.-S. Chun, and M.
Bernfield, American Society of Cell Biology. 1994. 1813
(Abstr.); Subramanian et al., 1997). Both tyrphostin A25
and methyl 2,5 dihydroxycinnamate, protein tyrosine ki-
nase inhibitors, prevented the PMA-accelerated shedding
of syndecan-1 (Fig. 1 A) and syndecan-4 (Fig. 1 B) ec-
todomains.
The thrombin receptor (also known as proteinase-acti-
vated receptor–1 [Dery and Bunnett, 1999; Dery et al.,
1998]) is activated by the 14–amino acid thrombin recep-
tor agonist peptide (TRAP), which has no inherent pro-
teolytic activity (Troyer et al., 1992; Dery and Bunnett,
1999). Tyrphostin A25 inhibited TRAP-accelerated shed-
ding of syndecan-1 (Fig. 1 C) and syndecan-4 (Fig. 1 D)
ectodomains, as previously reported for SVEC4-10 cells
(Subramanian et al., 1997). Because syndecan-1 and -4
ectodomains are in the fluids that surround injured tissues
(Subramanian et al., 1997), we reasoned that cellular stress
may accelerate shedding. We tested whether hyperosmo-
larity and the stress response agonist, ceramide, accelerate
syndecan ectodomain shedding. Shedding of syndecan-1
and -4 ectodomains was accelerated by treatment of
NMuMG cells with 700 mOsm NaCl (Fig. 1, E and F) and
ceramide (Fig. 1, G and H). This shedding was also inhib-
ited by tyrphostin A25. Similar results were observed
Figure 1. Accelerated shed-
ding of syndecan-1 and -4 de-
pends on protein tyrosine ki-
nase activity. (A and B)
NMuMG epithelial cells were
incubated with 4aPDD (0.5
mM), an inactive PMA ana-
logue or PMA for 30 min and
in the presence or absence of
tyrphostin A25 (5 mg/ml) or
methyl 2,5, dihydroxycin-
namate (5 mg/ml). NMuMG
cells were incubated with or
without the following: (C and
D) 100 mM TRAP, or (E and
F) 700 mOsm NaCl, or (G
and H) 100 mM ceramide for
2 h in the presence or absence
of tyrphostin A25 (5 mg/ml).
Conditioned media were har-
vested and applied to cationic
Immobilon-N membranes for
dot blot analysis using ECL detection. Syndecan-1 (A, C, E, and G) and syndecan-4 (B, D, F, and H) ectodomains were detected by
ECL using mAb 281-2 and MSE-4 antiserum, respectively. Results are expressed as the amount of syndecan ectodomain shed in AU
quantified by densitometric scanning and analyzed with NIH image software. Each point represents the mean 6 SD of triplicate deter-
minations. For each shedding agonist assayed, incubation with inhibitor alone had no effect on the level of shedding compared with the
untreated control. 
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when SVEC4-10 cells were assayed. Sphingomyelinase (1
U/ml), which produces ceramide, sorbitol (700 mOsm),
NaCl (as low as 400 mOsm), and heat shock (42
 
8
 
C) also
accelerated shedding of syndecan-1 and -4 ectodomains
(data not shown). These results indicate that shedding of
syndecan-1 and -4 ectodomains can be accelerated by
agents that mediate cellular responses to stress (Rosette
and Karin, 1996; Verheij et al., 1996) and, therefore, impli-
cate the c-Jun NH
 
2
 
-terminal/stress–activated protein ki-
nase (JNK/SAPK) pathways in accelerated shedding (Ky-
riakis and Avruch, 1996). Thus, shedding of syndecan
ectodomains accelerated by PMA, thrombin receptor acti-
vation, and cellular stress involves protein tyrosine kinase
(PTK) activity. Cell morphology and viability were not af-
fected during these assays, except for minimal cell retrac-
tion under hypertonic conditions and in the presence of
ceramide.
 
Inhibition of Protein Kinase C Activity Prevents 
Shedding Accelerated by PMA and Cellular Stress but 
Not by Receptor Activation
 
To determine whether syndecan ectodomain shedding ac-
celerated by PMA, thrombin, and EGF receptor activa-
tion, or cellular stress involves PKC activity, we tested
whether bisindolylmaleimide I, a potent and selective in-
hibitor of PKC (Toullec et al., 1991), affected shedding.
Bisindolylmaleimide I completely blocked PMA-acceler-
ated shedding of syndecan-1 (Fig. 2 A) and -4 (Fig. 2 B).
Shedding of syndecan-1 and -4 accelerated by both hyper-
osmolarity (Fig. 2, C and D) and ceramide (Fig. 2, E and
F) were also inhibited by bisindolylmaleimide I. In con-
trast, neither TRAP- nor EGF-accelerated shedding of
syndecan-1 or -4 (Fig. 2, G and H) were affected by bisin-
dolylmaleimide I. Similar results were observed using
SVEC4-10 cells. Thus, inhibition of PKC activity prevents
shedding of syndecan-1 and -4 ectodomains accelerated by
PMA and cellular stress, but does not affect thrombin or
EGF receptor–activated shedding. These results indicate
that different agonists activate distinct intracellular signal-
ing pathways to accelerate syndecan shedding.
 
Inhibition of MAP Kinase Activity Prevents Shedding 
Accelerated by Receptor Activation but Not by PMA
 
We asked whether inhibitors known to target mitogen-
activated protein kinase (MAP kinase) signaling systems
affect shedding. We tested whether the specific MAP ki-
nase inhibitors, PD98059 and SB202190, affected shedding.
PD98059 is a selective inhibitor of MAP kinase kinase,
which blocks the subsequent phosphorylation and activa-
tion of ERK MAP kinase in vitro and in vivo (Alessi et al.,
1995; Dudley et al., 1995). PD98059 (at 
 
#
 
50 
 
m
 
M) did not
inhibit PMA-accelerated shedding of syndecan-1 (Fig. 3
A) or syndecan-4 (Fig. 3 B) ectodomains from NMuMG
cells, but did block the EGF-accelerated (Fig. 3, C and D)
and TRAP-accelerated (Fig. 3, E and F) shedding of these
ectodomains. PD98059 does not affect cell viability at con-
centrations up to 100 
 
m
 
M (Desdouits-Magnen et al., 1998),
and no change in cell morphology was seen during the as-
says. SB202190 is a specific inhibitor of the p38 MAP ki-
nase pathway both in vitro and in vivo (Lee et al., 1994;
Cuenda et al., 1995). SB202190 (at 
 
#
 
50 
 
m
 
M) did not in-
hibit PMA- or receptor-activated shedding of syndecan-1
or -4 (data not shown). These results suggest that both
stress- and receptor-activated, but not PMA-accelerated
shedding involve MAP kinase activity.
 
PMA Causes Syndecan Ectodomain Shedding from the 
Cell Surface
 
P3X63 cells, a mouse plasma cell line, express abundant
cell surface syndecan-1, have barely detectable levels of in-
tracellular syndecan-1, and shed syndecan-1 at a low con-
stitutive rate. Immunoprecipitation and dot blot analysis
of P3X63 cell lysates and conditioned media showed that
PMA treatment causes cell surface syndecan-1 to be rap-
idly lost with the concomitant appearance of the shed syn-
Figure 2. Shedding acceler-
ated by PMA and stress but
not by receptor activation de-
pends on protein kinase C ac-
tivity. NMuMG cells were in-
cubated (A and B) for 30 min
with PMA or 4aPDD (0.5
mM). NMuMG cells were in-
cubated (C and D) for 2 h
with or without the following:
700 mOsm NaCl, or (E and
F) 100 mM ceramide, or (G
and H) 10 ng/ml EGF, or 100
mM TRAP. Each agonist was
assayed in the absence or
presence of bisindolylmale-
imide I (Bis., 1 mM). Condi-
tioned media were assayed
for syndecan-1 (A, C, E, and
G) and syndecan-4 (B, D, F,
and H) ectodomains by dot blot analysis as in Fig. 1. Quantitation was done as in Fig. 1, and each point represents the mean 6 SD (n 5
3). For each shedding agonist assayed, incubation with inhibitor alone had no effect on the level of shedding compared with the un-
treated control. 
The Journal of Cell Biology, Volume 148, 2000 816
 
decan-1 ectodomains in the conditioned media (Fitzger-
ald, M.L., J.-S. Chun, and M. Bernfield, American Society
of Cell Biology. 1994. 1813 (Abstr.)). We have now la-
beled syndecan-1 at the surface of these cells with biotin-
ylated mAb 281-2 at 4
 
8
 
C to avoid constitutive shedding.
Bright fluorescence and occasional punctate stain was
seen at the cell surface (Fig. 4 A). After PMA treatment of
these cells, the syndecan-1 stain was reduced after 5 min
and was completely lost after 30 min, except for some re-
sidual punctate stains (Fig. 4 B). To confirm that shedding
is from the cell surface, we asked whether trypsinization of
unlabeled P3X63 cells at 4
 
8
 
C, which removes cell surface
syndecan-1 quantitatively (Jalkanen et al., 1987), prevents
subsequent PMA-induced shedding. No syndecan-1 ec-
todomain was detected in the conditioned media after
PMA treatment of trypsinized cells (data not shown).
Moreover, pretreatment of cells with cytochalasin D (1
 
m
 
g/ml) or colchicine (50 
 
m
 
M) does not inhibit PMA-accel-
erated shedding, and antibody-induced cross-linking of cell
surface syndecan-1 actually prevents accelerated shedding
(data not shown). Thus, accelerated syndecan-1 ectodo-
main shedding is a cell surface event.
 
A Cell Surface–associated Proteolytic Activity Is 
Responsible for Accelerated Shedding
 
We next evaluated whether the proteolytic activity re-
sponsible for cleavage of the core protein and shedding of
the ectodomain is soluble or membrane-associated. For
these assays, PMA-treated human ARK cells and un-
treated mouse P3X63 cells were either mixed together or
separated from each other by a Transwell membrane. In
both assays, a constant number of P3X63 cells and a vary-
ing number of ARK cells were used. Human and mouse
syndecan-1 ectodomains were distinguished using mAb
DL-101 and 281-2, respectively. When cells were mixed to
allow cell–cell contact, the PMA-treated ARK cells accel-
erated shedding of the syndecan-1 ectodomain from the
untreated P3X63 cells (Fig. 5 A). However, when a Trans-
well membrane separated the cells, the PMA-treated
ARK cells did not accelerate shedding from the untreated
P3X63 cells (Fig. 5 B). Similar results were observed when
the same experiments were performed using PMA-treated
P3X63 cells and untreated ARK cells (data not shown).
These results indicate that the proteolytic activity respon-
sible for shedding is cell-associated rather than soluble.
Further, because this proteolytic activity can act on adja-
cent cells, it likely acts at the cell surface.
 
PMA-accelerated Shedding of Syndecan-1 Ectodomains 
Is Due to Cleavage at a Juxtamembrane Site in the
Core Protein
 
We previously showed that the GAG-free syndecan-1 and
-4 ectodomain core proteins, released from cultured cells,
were the same size regardless of whether shed constitu-
tively, accelerated by PMA, or receptor activation, or by
direct plasmin or thrombin treatment (Subramanian et al.,
1997). Based on the relative molecular mass, which was
determined by SDS-PAGE analysis of the shed ecto-
domains and the transmembrane proteoglycans (Jalkanen
et al., 1987; Rapraeger et al., 1987; Subramanian et al.,
1997), we predicted that cleavage occurs at a juxtamem-
brane site in the core protein ectodomain.
We constructed a putative uncleavable syndecan-1 mu-
tant by replacing 15 amino acids of the wild-type syn-
decan-1 juxtamembrane domain with the corresponding
amino acid sequence of the human CD4 T cell transmem-
Figure 3. Inhibition of MAP kinase activity pre-
vents shedding accelerated by receptor activation
but not by PMA. NMuMG cells were incubated
(A and B) for 30 min with or without 0.5 mM
PMA, or (C and D) for 2 h with or without 10 ng/
ml EGF, or (E and F) for 2 h with or without 100
mM TRAP. Each agonist was assayed in the ab-
sence or presence of PD98059 (20 mM). Condi-
tioned media were analyzed by dot blot for syn-
decan-1 (A, C, and E) and syndecan-4 (B, D, and
F) ectodomains as in Fig. 1. Quantitation was
done as in Fig. 1 and each point represents the
mean 6 SD (n 5 3). For each shedding agonist
assayed, incubation with inhibitor alone had no
effect on the level of shedding compared with the
untreated control. 
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brane antigen (Fig. 6 A), and tested whether the mutant
was resistant to PMA-accelerated shedding. CD4 does not
undergo PMA-accelerated shedding (Wang et al., 1987;
Shin et al., 1991), suggesting that CD4 is not cleaved by the
proteolytic activity that sheds syndecan-1. Whereas PMA
treatment of COS-7 cells transfected with wild-type synde-
can-1 (syn1-WTJM) released the soluble ectodomain, an
activity inhibited by a peptide hydroxamate (cf. below),
PMA did not accelerate release of syndecan-1 from cells
transfected with the syn1-CD4 juxtamembrane mutant
(Fig. 6 B). Similar results were observed using CHO cells
and HT-1080 human fibrosarcoma cells (data not shown).
Thus, the core protein is cleaved in the juxtamembrane re-
gion within 15 amino acids from the cell surface.
 
Hydroxamate Inhibitors of Metalloproteinases Prevent 
Accelerated Shedding
 
Because the accelerated shedding of a variety of cell sur-
face protein ectodomains has been shown to require MP
activity (Hooper et al., 1997), we examined a panel of MP
inhibitors for their effect on PMA-accelerated shedding of
syndecan-1. We found that the transition metal ion chela-
 
tors, EDTA and 1,10 phenanthroline, and the hydroxamic
acid–based MP inhibitor actininon (Sayama et al., 1995),
blocked PMA-accelerated shedding of syndecan-1 ecto-
domains from P3X63 and SVEC4-10 cells in a dose-depen-
dent manner, but phosphoramidon, a zinc chelator specific
for thermolysin, did not affect accelerated shedding (Fitz-
gerald, M.L., and M. Bernfield, American Society of Cell
Biologists. 1997. 2286 (Abstr.)). Inhibitors of aspartic, cys-
teine, and serine proteinases (pepstatin A, E-64, benzami-
dine, leupeptin, and PMSF) did not block PMA-acceler-
ated shedding (data not shown).
Thus, we tested the effects of hydroxamic acid-based
MP inhibitors, initially developed to inhibit shedding of
pro-TNF-
 
a
 
 (Odake et al., 1994; Sayama et al., 1995; Woj-
towicz-Praga et al., 1997; Pratt et al., 1998) on syndecan-1
and -4 shedding accelerated by PMA, receptor activation,
and cellular stress. The peptide hydroxamates BB-2116 and
BB-1101 reduced the shedding of syndecan-1 (Fig. 7 A)
and syndecan-4 (Fig. 7 B) ectodomains from PMA-treated
NMuMG cells in a concentration-dependent manner with-
out affecting cell morphology or viability; the IC
 
50
 
 was
 
z
 
0.1 
 
m
 
M. Similar results were observed when P3X63
and SVEC4-10 cells were used (data not shown). EGF-,
TRAP-, and ceramide-accelerated shedding of syndecan-1
(Fig. 7, C and E) and syndecan-4 (Fig. 7, D and F) ecto-
domains were also inhibited by hydroxamate BB-1101.
The control hydroxamate compound BB-3861, which lacks
the zinc-binding domain, had no effect on syndecan shed-
ding at concentrations up to 10 
 
m
 
M (data not shown).
These results suggest that syndecan-1 and -4 shedding, ac-
celerated by each of the agonists tested, depends on metal-
loproteinase activity.
 
The Matrix-associated Metalloproteinase Inhibitor 
TIMP-3 Prevents Accelerated Shedding
 
Because the peptide hydroxamate MP inhibitors pre-
vented syndecan-1 and -4 ectodomain shedding, we tested
Figure 5. A membrane-associated proteolytic activity is responsi-
ble for accelerated shedding. P3X63 cells were coincubated for 15
min with human ARK cells that had been pretreated with or
without PMA for 15 min and washed twice with serum-free me-
dia. Cells were (A) mixed together or (B) separated from each
other by a Transwell membrane. A constant number of P3X63
cells (5 3 106) and a varying number of ARK cells were used.
Conditioned media were analyzed by dot blot using mAb 281-2
to detect syndecan-1 shed from the surface of P3X63 cells. Quan-
titation was done as in Fig. 1 and each point represents the mean 6
SD (n 5 3).
Figure 4. Syndecan ectodomains are shed by proteolytic cleavage
at the cell surface. Live P3X63 mouse plasma cells were incu-
bated for 30 min at 48C with biotinylated mAb 281-2 against the
syndecan-1 ectodomain before treatment with or without 0.5 mM
PMA for 30 min at 378C. Cells were fixed and labeled with FITC-
avidin for immunofluorescent detection of cell surface syndecan-1
on untreated (A) or PMA-treated (B) cells.The Journal of Cell Biology, Volume 148, 2000 818
members of the tissue inhibitor of metalloproteinase
(TIMP) family of secreted MMP inhibitors (Murphy and
Willenbrock, 1995; Anand-Apte et al., 1996; Gomez et al.,
1997). TIMP family members have distinct expression pat-
terns (Leco et al., 1994), form complexes with different
progelatinases (Murphy and Willenbrock, 1995; Gomez
et al., 1997; Butler et al., 1999b; Murphy et al., 1999), and
differ in their ability to bind heparin (Butler et al.,
1999b). PMA-accelerated shedding of both syndecan-1 and
-4 ectodomains from NMuMG cells (Fig. 8, A and B) is spe-
cifically inhibited by TIMP-3; TIMP-1 and TIMP-2 had
no effect on shedding at concentrations up to 20 mg/ml.
Similar results were observed when P3X63 and SVEC4-
10 cells were used (data not shown). TIMP-3 inhibition
was concentration-dependent; the IC50 was z5  mg/ml,
and PMA-accelerated shedding was completely pre-
vented in the presence of 20 mg/ml (z0.8 mM) TIMP-3
(Fig. 8, C and D). To determine whether shedding ac-
celerated by physiological agonists is also inhibited by
TIMP-3, we tested the effect of TIMP-3 on EGF-,
TRAP-, and ceramide-accelerated shedding of synde-
can-1 and -4 ectodomains. TIMP-3 reduced EGF and
TRAP receptor–activated shedding from SVEC4-10 cells
(Fig. 9, A and B), and ceramide-induced shedding of these
syndecans from NMuMG cells (Fig. 10, C and D). Thus,
shedding accelerated by PMA and a variety of physiological
agonists requires a TIMP-3–sensitive MP activity.
Hydroxamates, but Not TIMP-3, Prevent
Constitutive Shedding
All cultured cells studied shed syndecan ectodomains as
part of normal turnover (Yanagishita and Hascall, 1992;
Kim et al., 1994; Yanagishita, 1998). To evaluate whether
this constitutive shedding differs from accelerated shed-
ding, we tested the effects of the peptide hydroxamates
and TIMP-3 on constitutive shedding from SVEC4-10
cells in 14-h assays. Peptide hydroxamates BB-2116 and
BB-1101 reduced the level of syndecan-1 (Fig. 10 A) and
syndecan-4 (Fig. 10 B) shedding in a concentration-depen-
dent manner; the IC50 values were z10-fold higher than
those observed for inhibition of PMA-accelerated shed-
ding (Fig. 7). In contrast, increasing concentrations of
TIMP-3 had no effect on syndecan-1 and -4 ectodomain
shedding from SVEC4-10 cells (Fig. 10, C and D). TIMP-1
and TIMP-2 also had no effect on constitutive shedding at
concentrations up to 20 mg/ml, and similar results were ob-
served when NMuMG cells were used (data not shown).
These results suggest that constitutive shedding involves a
metalloproteinase. However, this activity differs from the
MP activity that mediates accelerated shedding.
Discussion
In this study, we demonstrate that the ectodomains of syn-
decan-1 and -4 are shed from the cell surface after activa-
tion of multiple intracellular signaling pathways by diverse
physiological effectors. This shedding involves the activity
of a cell surface metalloproteinase (sheddase) that is spe-
cifically inhibited by TIMP-3. Shedding of the syndecan-1
core protein involves cleavage in its juxtamembrane do-
main at the extracellular face of the plasma membrane. Fi-
nally, the enzymatic activity responsible for regulated
shedding differs from that involved in constitutive shed-
ding. Ectodomain shedding converts syndecans from cell
surface receptors or coreceptors to soluble HS proteogly-
can effectors. Because shedding is regulated by physiologi-
cal mediators, the syndecan ectodomains can be shed in
response to specific developmental and pathophysiologi-
cal cues. Considering their large number of potential
ligands, the shed syndecan ectodomains are likely to have
roles in morphogenesis, tissue repair, and host defense.
Multiple Signaling Pathways Regulate Syndecan-1
and -4 Ectodomain Shedding
Diverse agonists were identified as accelerators of synde-
can-1 and -4 ectodomain shedding (Fig. 11). Shedding ac-
celerated by activation of the EGF and thrombin recep-
tors correlates best with activation of the ERK MAP
kinase pathway, but does not appear to involve PKC acti-
vation. In contrast, agonists associated with cellular stress
(e.g., hyperosmolarity and ceramide) appear to require
PKC activation upstream of the JNK/SAPK MAP kinase
Figure 6. PMA-accelerated shedding of syndecan-1 ectodomains
results from cleavage at a juxtamembrane site in the core protein.
(A) Schematic depiction of wild-type (WT) syndecan-1 and the
CD4-juxtamembrane (JM) mutant syndecan-1. The JM region of
the ectodomain is shown both with the WT amino acid sequence
and with the CD4-JM domain mutant sequence (bold face). (B)
COS-7 cells were transiently transfected with either the WT syn-
decan-1 or the CD4-JM mutant. Cells were incubated with or
without PMA (0.5 mM for 15 min) in the absence or presence of
peptide hydroxamate BB-1101 (1 mM). Syndecan-1 ectodomains
in the conditioned media were assayed by dot blot analysis and
quantitation was done as in Fig. 1. Each point represents the
mean  6  SD (n 5 3).Fitzgerald et al. Syndecan Ectodomain Shedding Is Regulated 819
pathway. Inhibition of p38 MAP kinase activity by SB
202190 had limited effect on shedding accelerated by any
of the agonists tested. Taken together, these results strongly
correlate syndecan ectodomain shedding with the action
of specific MAP kinase signaling pathways.
Syndecan-1 and -4 ectodomains are also shed in re-
sponse to phorbol ester activation of PKC. Thus, it is likely
that physiological effectors that produce diacylglycerol
would also accelerate shedding. In the cell types studied,
shedding in response to phorbol esters does not appar-
ently require MAP kinase activity, but this regulation may
be cell type–specific. For example, whereas the phospho-
inositide 3-kinase inhibitors, wortmannin and LY 294002,
do not inhibit EGF and thrombin receptor–activated
shedding in epithelial and endothelial cells, these effec-
tively inhibit insulin-induced shedding in 3T3-L1 adipo-
cytes (Fitzgerald, M., and M. Bernfield, unpublished re-
sults).
The shedding accelerated by each agonist involves PTK
activity. This activity could phosphorylate the syndecan
core protein cytoplasmic domain, but because cells acti-
vated with PMA can cleave the syndecan ectodomains
from unactivated adjacent cells, shedding does not appar-
ently require such phosphorylation. Syndecan-1 and -4
shedding is accelerated after pervanadate inhibition of
protein tyrosine phosphatases (Reiland et al., 1996; Fitz-
gerald, M., unpublished results), and this phosphorylation
is undetectable or detected at low levels in resting cells
(Ott and Rapraeger, 1998) that shed syndecan ectodo-
mains constitutively. Thus, the PTK activity may phos-
phorylate the cleaving enzyme(s) and/or other unidenti-
fied components of the shedding system.
In each assay, we tested the effect of the PKC, MAP ki-
nase, or PTK inhibitor alone. In no case did the inhibitor
affect the level of shedding compared with the untreated
control. These data suggest that these inhibitors do not af-
fect the synthesis, glycosylation, or transport of syndecans
to the cell surface during the brief assay periods (30 min to
2 h). Each cell line tested responded nearly identical to
each of the agonists of syndecan-1 and -4 ectodomain
shedding, suggesting that the same process(es) mediate
shedding of both HSPGs. Because multiple distinct intra-
cellular pathways are involved, our results contrast with
studies that suggest a common shedding system for a vari-
ety of proteins (Arribas et al., 1996; Mullberg et al., 1997).
However, in concert with the proposed common shedding
system, protein cleavage is at a juxtamembrane site, the
sheddase does not appear to cleave a specific sequence,
and shedding is inhibited by similar concentrations of pep-
tide hydroxamates (Hooper et al., 1997; Hooper and
Turner, 1999). Identification of the enzyme(s) involved in
shedding will be required to document the differences in
these shedding mechanisms.
Syndecan Ectodomains Are Shed from the Cell Surface
Syndecan ectodomain shedding is a cell surface event. Flu-
orescently tagged syndecan-1 is lost from the cell surface
within 30 min after PMA treatment of P3X63 cells, and
pretrypsinization of cells to remove cell surface syndecan-1
prevents accelerated shedding, suggesting that the core
protein cleavage site is at the extracellular face of the
plasma membrane. Introduction of a 15–amino acid region
from human CD4 into the corresponding juxtamembrane
region of the syndecan-1 core protein ectodomain pre-
vents accelerated shedding, indicating that the core pro-
tein cleavage site is within 15 amino acid residues of the
plasma membrane. We are currently in the process of
identifying the precise cleavage site.
The enzymatic activity responsible for this cleavage
Figure 7. Accelerated shed-
ding is inhibited by peptide
hydroxamates. (A and B)
NMuMG cells were incubated
with or without PMA (0.5 mM
for 30 min) in the presence or
absence of peptide hydroxa-
mate BB-2116 or BB-1101 at
the indicated concentration.
(C and D) SVEC4-10 cells
were incubated for 2 h with or
without 10 ng/ml EGF or 100
mM TRAP in the presence or
absence of 1 mM BB-1101. (E
and F) NMuMG cells were in-
cubated for 2 h with or with-
out 100 mM ceramide in the
presence or absence of 1 mM
BB-1101. Syndecan-1 (A, C,
and E) and syndecan-4 (B, D,
and F) ectodomains in the
conditioned media were as-
sayed by dot blot analysis as
in Fig. 1. Quantitation was
done as in Fig. 1 and each
point represents the mean 6 SD (n 5 3). For each shedding agonist assayed, incubation with inhibitor alone (1 mM) reduced the level
of shedding compared with the untreated control.The Journal of Cell Biology, Volume 148, 2000 820
appears to be associated with the cell surface because con-
tact with PMA-activated cells causes accelerated shedding
from untreated cells. Because the syndecan and the cleav-
ing activity are both linked to the plasma membrane, and
shedding is blocked at 48C (Jalkanen et al., 1987), shed-
ding is also likely regulated by changes in membrane dy-
namics (e.g., fluidity and actin filament association).
Regulated Syndecan Ectodomain Shedding Is Mediated 
by a TIMP-3–sensitive Metalloproteinase
In each of the cell types tested, accelerated shedding of
syndecan-1 and -4 was blocked by the peptide hydroxa-
mates BB-2116 and BB-1101, which are compounds origi-
nally designed to inhibit zinc-dependent matrix MPs (MMPs)
(Odake et al., 1994; Wojtowicz-Praga et al., 1997; Pratt et
al., 1998). High concentrations of these compounds inhibit
ectodomain shedding of a diverse group of transmembrane
proteins (Hooper et al., 1997). Indeed, BB-2116 and BB-
1101 inhibit accelerated syndecan shedding from each of
the cell types at z100-fold greater concentrations than
needed to inhibit MMP-1, soluble human fibroblast colla-
genase. These data suggest that the syndecan sheddase is
an MP, but not an MMP.
The physiological MMP inhibitor, TIMP-3, but not the
closely related inhibitors TIMP-1 and TIMP-2, also inhib-
its accelerated syndecan shedding. Between them, TIMP-1
and TIMP-2 can inhibit the activity of all known MMPs
tested at the concentrations used in this study (Murphy
and Willenbrock, 1995), again suggesting that the synde-
can sheddase is not a known MMP. TIMP-3 is unique
among the TIMPs in that it contains a heparin binding mo-
tif (Butler et al., 1999a) by which it is largely bound to the
extracellular matrix (Pavloff et al., 1992; Leco et al., 1994;
Kishnani et al., 1995). Indeed, this binding appears to po-
tentiate its inhibitory activity (Butler et al., 1999a). TIMP-3
is expressed by a large variety of tissues and cells (Re-
ponen et al., 1995) and is induced by treatment of cells
with cytokines, growth factors, and anti-inflammatory agents
(Leco et al., 1994), indicating that it may regulate tissue re-
modeling.
The affinity of TIMP-3 for HS chains may expand its
role in syndecan ectodomain shedding. Syndecan HS
chains might localize TIMP-3 to the cell surface, the site of
ectodomain shedding, thereby potentiating its inhibitory
activity (Amour et al., 1998). Conversely, the HS chains on
soluble syndecan ectodomains could reduce its ability to
inhibit at the cell surface. Further, this modulation of
TIMP-3 activity could affect the shedding of membrane-
anchored proteins such as L-selectin, TNF-a, and the inter-
leukin 6 receptor that are sensitive to TIMP-3 (Hargreaves
et al., 1998; Borland et al., 1999).
Figure 8. PMA-accelerated shedding is specifically inhibited by
TIMP-3. (A and B) NMuMG cells were treated with PMA (0.5
mM for 30 min) in the presence or absence of 20 mg/ml TIMP-1,
-2, or -3. (C and D) NMuMG cells were treated with or without
PMA (0.5 mM for 30 min) in the presence or absence of TIMP-3
at the indicated concentration. Syndecan-1 (A and C) and synde-
can-4 (B and D) ectodomains in the conditioned media were as-
sayed by dot blot analysis as in Fig. 1. Quantitation was done as
in Fig. 1 and each point represents the mean 6 SD (n 5 3). For
each shedding agonist assayed, treatment with TIMP-1, -2, or -3
alone (20 mM) had no effect on the level of shedding compared
with the untreated control.
Figure 9. Receptor- and stress-activated shedding is inhibited by
TIMP-3. (A and B) SVEC4-10 cells were treated with or without
10 ng/ml EGF or 100 mM TRAP, or (C and D) NMuMG cells
were treated with or without 100 mM ceramide for 2 h in the pres-
ence or absence of 20 mg/ml TIMP-3. The syndecan-1 (A and C)
and syndecan-4 (B and D) ectodomains in the conditioned media
were assayed by dot blot analysis as in Fig. 1. Quantitation was
done as in Fig. 1 and each point represents the mean 6 SD (n 5
3). For each shedding agonist assayed, treatment with TIMP-1,
-2, or -3 alone (20 mM) had no effect on the level of shedding
compared with the untreated control.Fitzgerald et al. Syndecan Ectodomain Shedding Is Regulated 821
Our results suggest that the syndecan sheddase is a zinc-
dependent MP. The enzyme is not likely a known MMP
because TIMP-1 or TIMP-2 does not inhibit shedding.
Furthermore, the activity is associated with the cell sur-
face, whereas most MMPs are secreted enzymes. How-
ever, the syndecan sheddase could be a member of the
membrane-type (MT)-MMPs. Although at least four MT-
MMP family members have been identified (Mattei et al.,
1997), MT1-MMP and MT2-MMP can be excluded as pos-
sible candidates because they are inhibited by TIMP-2
(Will et al., 1996; Butler et al., 1997). Indeed, it is not clear
whether TIMP-3 inhibits the syndecan sheddase directly
or another enzyme in a proteinase cascade involved in syn-
decan shedding.
The ADAMs family of membrane-spanning proteins
that combine features of both adhesion molecules and
proteinases (Wolfsberg and White, 1996; Blobel, 1997;
Black and White, 1998; Izumi et al., 1998) are also can-
didates for the syndecan sheddase. The sole mammalian
cell surface–associated metalloproteinase sheddase so far
identified is ADAM 17 (TACE). TACE cleaves the
ectodomain of TNF-a (Black et al., 1997; Moss et al.,
1997), and several other structurally and functionally unre-
lated transmembrane proteins. However, PMA acceler-
ates the shedding of syndecan-1 and -4 ectodomains from
a TACE-deficient fibroblast cell line (Black et al., 1997),
albeit at a reduced rate in comparison to P3X63, NMuMG
and SVEC4-10 cells (Fitzgerald, M., unpublished results),
indicating that TACE is not the syndecan sheddase.
Constitutive and Accelerated Syndecan Ectodomain 
Shedding Use Distinct Mechanisms
The enzymatic cleavage responsible for accelerated shed-
ding appears to be distinct from that involved in constitu-
tive shedding. The intact ectodomains of each mammalian
syndecan and the single Drosophila syndecan are constitu-
tively shed into the conditioned media of cultured cells
(Kim et al., 1994; Spring et al., 1994) as part of normal cell
surface HSPG turnover (Yanagishita and Hascall, 1992;
Yanagishita, 1998). In contrast with accelerated ectodo-
main shedding, constitutive syndecan ectodomain shed-
ding is not inhibited by TIMP-3 and its inhibition requires
z10-fold greater peptide hydroxamate concentrations.
These data suggest different proteolytic systems for accel-
erated and constitutive syndecan ectodomain shedding,
consistent with distinct cellular roles for these processes.
Functional Significance of Ectodomain Shedding
Solubilization of the ectodomains appears to be the major
consequence of syndecan shedding. For both constitutive
and accelerated shedding, the ectodomains appear to be
rapidly replaced on the cell surface (Subramanian et al.,
1997; Kainulainen, 1999). Many of the agents that acceler-
ate shedding are involved in tissue injury, suggesting that
the soluble ectodomains function during tissue repair and
host defense.
Shed soluble syndecan ectodomains are found in in-
flammatory fluids (Subramanian et al., 1997) where they
maintain proteolytic and growth factor balance. Indeed,
the agents that accelerate syndecan ectodoman shedding
are released and act during acute wound repair (Clark,
1996). Tissue injury is accompanied by cellular stress, ac-
cumulation of plasma- and neutrophil-derived proteases
(e.g., thrombin, plasmin, elastase, cathepsin G), and release
of growth factors (e.g., EGF, heparin-binding epidermal
growth factor-like growth factor, transforming growth fac-
tor-a), each of which accelerate syndecan shedding (Su-
bramanian et al., 1997). This shedding is modulated by
plasma-derived proteinase inhibitors (Kainulainen et al.,
1998), and by TIMP-3. The soluble syndecan-1 ectodomain
acts as a dominant-negative inhibitor of the proliferative
response of cells to HB-EGF (Wang, H., and M. Bernfield,
unpublished results) and FGF-2 (Kato et al., 1998), two of
the major growth factors involved in wound repair (Flau-
menhaft and Rifkin, 1992; Marikovsky et al., 1993; Abra-
ham and Klagsbrun, 1996). Soluble syndecan ectodomains
can also modify proteolytic activities at sites of inflamma-
tion by binding to neutrophil-derived proteases and reduc-
ing their interactions with their physiological inhibitors
(Kainulainen et al., 1998). Thus, ectodomain shedding
provides a mechanism for balancing the proteinase and
growth factor activities needed for normal wound repair.
The action of the soluble ectodomains during tissue in-
jury is transient. Tissue repair is accompanied by accumu-
lation of fibrotic deposits of interstitial extracellular ma-
trix components, including fibrillar collagens, fibronectin
and tenascin (Clark, 1996). These extracellular matrix
Figure 10. Constitutive shedding of syndecan-1 and -4 is inhib-
ited by peptide hydroxamates but not by TIMP-3. SVEC4-10
cells were incubated for 14 h in the presence or absence of the in-
dicated concentration of (A and B) peptide hydroxamate BB-
2116 and BB-1101, or (C and D) TIMP-3. The syndecan-1 (A and
C) and syndecan-4 (B and D) ectodomains in the conditioned
media were assayed by dot blot analysis as in Fig. 1. Quantitation
was done as in Fig. 1 and each point represents the mean 6 SD (n 5
3). TIMP-1 and TIMP-2 (20 mM) did not inhibit constitutive
shedding in this assay, and treatment with the PTK, PKC, or
MAPK inhibitors alone did not affect the level of shedding com-
pared with untreated controls during the 2 h shedding assays.The Journal of Cell Biology, Volume 148, 2000 822
component deposits bind the soluble syndecan ectodo-
mains, thus, limiting their activity and effectively terminat-
ing their influence. Thus, shed syndecan ectodomains are
newly defined mediators of inflammation. These findings
suggest a novel physiologic role for the soluble syndecan
ectodomains and new approaches to modulate the inflam-
matory process.
Accelerated syndecan shedding accompanies host cell
invasion by certain microbial pathogens. In the case of
Pseudomonas aeruginosa, the organism accelerates shed-
ding to enhance its infectivity. The secreted virulence fac-
tor, LasA (staphylolysin), accelerates syndecan-1 shedding
by activation of PTKs and a zinc-dependent MP (Park et al.,
2000). The mechanism by which syndecan shedding en-
hances infectivity is unclear.
Syndecan-1 and -4 can function in the maintenance of
epithelial morphology and the formation of focal contacts,
respectively (Kato et al., 1995; Woods and Couchman,
1998; Bernfield et al., 1999). These functions depend on
the adhesion of these syndecans to the extracellular matrix
as coreceptors for integrins. Integrin-mediated adhesion to
the extracellular matrix is central to growth control, and
could activate the same MAP kinase/ERK pathways as
those responsible for accelerated shedding of these synde-
can ectodomains (Thomas and Brugge, 1997). Thus, syn-
decan ectodomain shedding via activation of MAP kinase
pathways suggests the possible involvement of cell surface
HSPG shedding in growth control, as suggested many
years ago by Kraemer and Tobey (1972). This involvement
could operate via the role of syndecans in controlling cell
shape through their action on actin cytoskeleton organiza-
tion and contractility (Burridge and Chrzanowska-Wod-
nicka, 1996).
Syndecan ectodomain shedding is a highly regulated
means of delivering soluble syndecan ectodomains to tis-
sues. Additionally, syndecan ectodomains can be solubi-
lized by the direct action of extracellular proteinases (e.g.
plasmin, thrombin, elastase) (Subramanian et al., 1997).
However, acceleration of syndecan ectodomain shedding
by physiological mediators indicates that shedding is a re-
sponse to specific developmental and pathophysiological
cues. Indeed, regulated shedding likely accompanies nor-
mal development, as the soluble syndecan-1 ectodomain is
found in early mouse embryos (Sutherland et al., 1991).
Just as every adherent cell type expresses at least one of
the syndecan family members at the cell surface (Kim et al.,
1994), we hypothesize that all syndecan-expressing cells
have a mechanism to regulate syndecan ectodomain shed-
ding. A further understanding of these mechanisms should
lead to devising molecules that selectively promote or pre-
vent syndecan shedding and to their pharmacological use
to modify inflammatory processes.
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Note Added in Proof. After this paper was accepted, a publication ap-
peared (EMBO (Eur. Mol. Biol. Organ.) J. 1999. 18:6962–6972) that dem-
onstrated that TGFa and L-selectin are shed after activation of the ERK
MAP kinase pathway, which is similar to the syndecan-1 and -4 shedding
reported here.
Figure 11. Syndecan ecto-
domain shedding. The synde-
can ectodomains can be shed
intact by proteolytic cleavage
of their core proteins, yield-
ing soluble HSPGs that retain
the binding properties of
their cell surface counter-
parts. Shedding of syndecan-1
and -4 ectodomains from the
cell surface is accelerated by
PMA and a variety of physio-
logical effectors (e.g., EGF
family members, thrombin,
hyperosmolarity, sphingomy-
elinase, and ceramide) via ac-
tivation of multiple intracel-
lular signaling pathways.
These signals converge on a
TIMP-3–sensitive cell sur-
face metalloproteinase sys-
tem that cleaves the core pro-
tein within 15 amino acids of
the cell surface, and can act
on unstimulated adjacent
cells. Shedding is stimulated
by tissue injury and these syn-
decan ectodomains are found in inflammatory fluids (Subramanian et al., 1997) where they modulate the activities of growth factors and
proteinases (Kainulainen et al., 1998; Kato et al., 1998). See text for details.Fitzgerald et al. Syndecan Ectodomain Shedding Is Regulated 823
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